Hochschulschrift
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
- Alternative title
-
Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Dimensions
-
30 cm
- Extent
-
31 Blätter
- Notes
-
Illustrationen, Diagramme
Enthält Sonderabdrucke
Friedrich-Alexander-Universität Erlangen-Nürnberg, Dissertation, 2016
- Classification
-
Medizin, Gesundheit
- Table of contents
- Rights
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Last update
-
11.06.2025, 1:38 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
Time of origin
- 2016
Other Objects (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?
Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?
Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?